• Licensed for use with USG projects                                                                        
  • Platform can be used for a variety of target antigens
  • Libraries of yeast and phage displayed Complementarity-determining
  • Design and selection of V regions improves manufacturability
  • Production platform format improves product attributes
  • Design supports similar pharmacokinetics for co-mixtures
  • Reduces potential for drug product antigenicity
  • Enables standard, systematic formulation approach with reduced aggregation and degradation
  • Platform provides for optimization of a variety of antibody characteristics and humanization